2021 Annual Meeting Radiopharmaceutical Therapy Master Class
Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies. This session will focus on clinical indications, difficult cases, medical physics considerations, development of standard operating procedures for clinical implementation, billing and troubleshooting theranostic delivery. Specifically, Radium-223, Lutetium-177 dotatate and Lutetium-177 PSMA-617 will be discussed. The session will include didactic presentation from physician experts from radiation oncology, nuclear medicine, medical oncology and medical physicists, with question and answer sessions to discuss practice implementation in various clinical settings (i.e. academic hospital vs community practice, nuclear medicine vs radiation oncology). The purpose of the Master Class is to increase physician, physicist, billing and administration understanding on how to effectively and safely develop a radiopharmaceutical program at their respective institutions.
This session was recorded at the 2021 ASTRO Annual Meeting, October 24-27, 2021.
Upon completion of this activity, participants should be able to:
- Discuss the relevant principles of physics, pharmacology and radiobiology for radiopharmaceutical therapies (RPTs).
- Identify clinical indications for RPTs that are currently approved for clinical use.
- Identify barriers and logistical steps for implementing RPT use in their own practice.
- Richard Wahl, MD
- Stephen Graves, PhD
- Ana P. Kiess, MD, PhD
- Phuoc T. Tran, MD, PhD
- Robert Frances Hobbs, PhD, DABR
- Jeff Michael Michalski, MD, MBA, FASTRO
- Jacqueline E. Zoberi, PhD
- Jonathan Strosberg,MD
- John Buatti, MD
- Hyun Kim, MD
- 0.00 Certificate of AttendanceThis activity was designated for 0.00 AMA PRA Category 1 Credit™.